OVERVIEW OF REGENLAB'S PATENTED TECHNOLOGIES
Andreas PIGNI
Legal Affairs, RegenLab SA
INTRODUCTION
RegenLab SA has established itself as a pioneer and leader in regenerative medicine, known for its innovative technologies that synergistically use platelet-rich plasma (PRP) in combination with various bioactive/therapeutic agents, providing cutting-edge solutions for a wide range of medical applications.
RegenLab's product range, backed by a strong patent portfolio, reflects a deep commitment to innovation.
The company's patented "all-in-one" tube systems simplify the preparation and application of PRP directly at the point of care, alone or in synergistic combination with other agents such as autologous thrombin serum (ATS), hyaluronic acid (HA, linear and cross-linked), calcium gluconate, antifibrinolytic substances, and many others.
Their extensive patent portfolio underlines their commitment to innovation in the development of new tissue engineering matrices (TEMs) and advanced cell therapy techniques, designed to improve therapeutic outcomes in a variety of medical disciplines, including orthopedics, dermatology, urogynecology and aesthetic medicine.
DETAILED OVERVIEW OF PATENT FAMILIES AND TECHNOLOGIES
1. PRP-A and bone marrow concentrate technologies, combination with cell extracts and cell culture
These core technologies involve methods and devices for preparing and using PRP and bone marrow concentrate (BMC), alone or in combination with other agents such as cell extracts, to support a range of therapeutic applications.
These systems are designed for efficient extraction and activation of PRP or BMC, which form the basis of the first therapeutic applications.
Basic technology and system design
The core innovation of this patent family concerns specialized container systems equipped with a combination of thixotropic gel and anticoagulant.
These containers are specially designed to optimize the separation of platelets and plasma from other blood components by centrifugation (to improve PRP yield and quality), for ease of use and clinical efficacy.
These systems facilitate the separation and activation of PRP to maximize its therapeutic potential.
The resulting platelet-rich plasma (PRP) is then ready to be combined with various therapeutic agents, including hyaluronic acid, and other cellular or biochemical additives, to enhance its regenerative properties.
-
Products/Brands : RegenACR®, RegenKit® Surgery, RegenKit® BCT, A-CP Kit®, Regen Fibrin Polymer, RegenKit® Extracell, Regen Extracell®, Regencell®, THT®, Cutecell®, A-PRP®, REGENPRP®, REGEN®, PRP®, Regenvet®.
-
Key patents : US11241458, US11110128, US11096966, US10881691, US10092598, US10080770, US10064894, US8529957, US9833478, US11389482, EP3395383B.
-
Main features : These patents relate to systems and methods for preparing cellular compositions from blood using containers/tubes containing an anticoagulant and a thixotropic gel, specialized for centrifuging whole blood to separate platelet-rich plasma from red blood cells.
-
Cutting-edge technology : These patents describe methods that optimize the separation and stabilization of PRP/BMC, ensuring their efficacy for a variety of clinical applications, particularly in the fields of musculoskeletal, wound healing and tissue regeneration. These systems are at the forefront of improving regenerative medicine practices, notably by isolating and activating PRP/BMC in sterile, closed environments, maximizing clinical efficacy and patient safety.
2. ATS alone and in combination with A-PRP for biological adhesives and membranes
This category includes technologies related to autologous thrombin serum (ATS), used alone or with PRP to create adhesives and biological membranes for surgery, wound healing and other applications, detailing methods that ensure efficient, high-purity thrombin serum production.
-
Products/brands : RegenKit® ATS, Regenwound™, A-CP ATS
-
Main patents : US10226516,
-
Innovative aspect: The technology encompasses state-of-the-art methods for creating thrombin serum using a thixotropic gel, which can be used independently or combined with PRP to create wound and tissue healing agents, demonstrating versatility and innovation in autologous treatments.
3. Combination therapies with hyaluronic acid
Building on the first generation of PRP technologies, RegenLab has developed advanced therapies combining PRP and hyaluronic acid, offering innovative solutions for linear (Cellular Matrix®) and cross-linked HA (RegenMatrix®) applications. These patents highlight the integration of PRP with HA to form innovative tissue engineering matrices that significantly advance the field of regenerative medicine by improving tissue repair and the management of conditions such as osteoarthritis.
-
Products/brands : Cellular Matrix® (linear HA), RegenMatrix® (cross-linked HA), PRPVISC® (cross-linked HA)
-
Main patents : US10272139, US8945537, US9517255, US10052349, EP2544697B1 EP3184114B, EP3854406B, EP2771241B, EP3903844, US20210346587, EP4337171
-
Cellular Matrix® (linear HA) : PRP and linear HA blending systems in integrated delivery devices, optimized for immediate clinical use.
RegenMatrix® (cross-linked AH) : is based on Cellular Matrix® technology and uses cross-linked HA for enhanced durability and efficacy, structural stability and longevity. Ideal for more demanding therapeutic contexts.
-
Key innovations:
-
Systems for mixing PRP and HA in single-chamber (all-in-one) or dual-chamber devices, to guarantee immediate and powerful use of the components.
-
These patents underline their usefulness in the creation of stable, effective regenerative matrices for clinical use.
-
Advantages :
-
RegenLab's approach combines PRP with biomaterials such as HA in products such as Cellular Matrix and RegenMatrix, which synergize the benefits of PRP and linear and cross-linked HA.
-
This integration enhances HA's regenerative properties, making it a powerful tool for tissue repair and osteoarthritis management.
4. CellularWound™ kits with calcium gluconate (CaGlu)
These kits represent a new development in RegenLab's product range, integrating PRP with calcium gluconate and HA, for enhanced wound healing applications.
-
Products/brands : CellularWound kits with
-
Main patents : EP3903844
-
Emerging innovations : The combination of PRP with HA and calcium gluconate offers a new approach to regenerative medicine, in particular for improving the structural integrity and longevity of the regenerative matrix used in tissue engineering.
-
Others : PRP and CaGlu improve the structural and therapeutic properties of injectable products, as demonstrated by patents such as US10272139 and US9517255, which describe the integration of calcium gluconate into PRP preparations.
5. CellularWound™ +, RegenWound™ + Kits with tranexamic acid (TXA)
This emerging field focuses on the development of kits combining PRP and tranexamic acid to improve hemostasis, wound healing and reduce/control bleeding. This combination aims to improve clot stability and efficacy in wound healing applications, with relevant technologies detailed in more recent patent filings that highlight TXA's role in regenerative therapies
-
Products/brands : Cellular wound kits with PCT application : PCT/EP2023/087473
6. Viral infections (COVID-19)
RegenLab is also tackling viral infections with a focus on COVID-19 through the development of specific plasma-based therapeutic applications, with a new use for plasma in immunomodulation and treatment protocols for the management of viral infections. Plasma preparations boost immune responses and promote healing in patients suffering from viral infections, demonstrating RegenLab's ability to adapt its technology to current global health needs and address emerging medical challenges.
-
Products/brands : Regenplasma®/A-
-
Main patents : EP4114526
7. Diagnostic kits for tumor detection
RegenLab is also exploring the field of diagnostics, in particular the isolation of extracellular vesicles (EVs) and exosomes for tumor diagnosis. The patents describe modifications made to the standard PRP preparation system to adapt it for diagnostic uses, demonstrating the versatility of the core technology to meet a variety of needs.
-
Applications : GB Application No. : 2315289.5, EP Priority Application No: 8
8. Innovative combination therapies with drugs, steroids, analgesics and other agents
RegenLab's patents also cover PRP combined with various pharmacological agents, enhancing therapeutic efficacy for targeted clinical needs.
Patents : US20190201504, EP3743079 encompassing a variety of combinations with therapeutic agents as specified in the claims
TABLES AND CHARTS
Technology |
Patents issued |
Patents pending |
A-PRP, Bone marrow concentrate, Glue and membranes, Combination with cell extracts, Cell culture |
13 |
3 |
ATS alone, combined with A-PRP |
10 |
5 |
Combination therapy, A-PRP and hyaluronic acid |
41 |
25 |
IVD kits - tumor diagnosis |
0 |
5 |
Viral infections (Covid 19) |
0 |
5 |
Technology |
Continent |
Patents issued |
Patents pending |
TOTAL |
A-PRP and related technologies |
Asia |
1 |
1 |
2 |
Europe |
1 |
1 |
2 |
|
North America |
11 |
1 |
12 |
|
ATS and related technologies |
Asia |
3 |
3 |
6 |
Europe |
1 |
1 |
2 |
|
North America |
1 |
0 |
1 |
|
Oceania |
1 |
0 |
1 |
|
Other |
4 |
1 |
5 |
|
Combination therapy(A-PRP and hyaluronic acid) |
Asia |
5 |
8 |
13 |
Europe |
5 |
2 |
7 |
|
North America |
5 |
3 |
8 |
|
Oceania |
3 |
1 |
4 |
|
Other |
23 |
11 |
34 |
|
IVD kits - tumor diagnosis |
Europe |
0 |
1 |
1 |
Other |
0 |
4 |
4 |
|
Viral infections (Covid 19) |
Asia |
0 |
1 |
1 |
Europe |
0 |
1 |
1 |
|
North America |
0 |
1 |
1 |
|
Oceania |
0 |
1 |
1 |
|
Other |
0 |
1 |
1 |
CONCLUSION
This review of RegenLab's patents on fundamental and advanced technologies highlights the company's strategic innovation in the development of next-generation tissue engineering matrices and cell therapies.
These patented technologies not only protect RegenLab's intellectual assets, but also strengthen its position as a leader in the field of regenerative medicine, equipped to deliver advanced therapeutic solutions on a global scale.
RegenLab is at the cutting edge of regenerative medicine with its sophisticated range of patented technologies that harness the potential of PRP and HA.
Its innovative suite of "all-in-one" tube systems simplifies the preparation and application of PRP, alone or in combination with other bioactive agents such as TSA, linear HA and cross-linked HA, to create branded products such as Cellular Matrix® and RegenMatrix®.
These products optimize the regenerative properties of HA and PRP, improving tissue repair and the management of pathologies such as osteoarthritis.
The company is also exploring new therapeutic formulations, such as combinations of PRP with HA and calcium gluconate, or with antifibrinolytic substances, demonstrating the versatility and breadth of RegenLab's technological advances.
These technologies are essential for developing new tissue engineering matrices (TEM) and advancing cell therapy approaches, offering improved therapeutic solutions in a variety of medical specialties, including orthopedics, dermatology, urogynecology and aesthetic medicine.
